- Report
- November 2023
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- February 2024
- 110 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- November 2023
- 432 Pages
Global
From €9154EUR$9,500USD£7,874GBP
- Report
- November 2023
- 230 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- January 2021
- 600 Pages
United States
From €2698EUR$2,800USD£2,321GBP
- Report
- November 2020
- 90 Pages
Global
From €5733EUR$5,950USD£4,932GBP
- Report
- June 2020
- 200 Pages
Global
From €6697EUR$6,950USD£5,761GBP
- Report
- January 2022
- 160 Pages
Global
From €9154EUR$9,500USD£7,874GBP
- Report
- January 2019
- 50 Pages
Global
From €1445EUR$1,500USD£1,243GBP
- Report
- June 2019
- 679 Pages
Global
€21199EUR$22,000USD£18,235GBP
- Drug Pipelines
- January 2018
- 18 Pages
Global
From €9636EUR$10,000USD£8,289GBP
- Drug Pipelines
- January 2018
- 17 Pages
Global
From €9636EUR$10,000USD£8,289GBP
- Report
- August 2019
- 212 Pages
Global
From €10595EUR$10,995USD£9,113GBP
- Report
- January 2021
- 124 Pages
Global
From €3469EUR$3,600USD£2,984GBP
- Report
- April 2023
- 129 Pages
Global
€4818EUR$5,000USD£4,144GBP
Apalutamide is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of androgens, hormones that can cause prostate cancer cells to grow. Apalutamide is used in combination with other treatments, such as hormone therapy, to slow the growth of prostate cancer. It is approved by the US Food and Drug Administration (FDA) for the treatment of non-metastatic castration-resistant prostate cancer.
Apalutamide is a relatively new drug, and is part of a growing class of prostate cancer treatments. It is one of several drugs that have been developed to target androgen receptors, which are proteins that can cause prostate cancer cells to grow. Other drugs in this class include enzalutamide and abiraterone.
Apalutamide is available in the US and Europe, and is marketed by several pharmaceutical companies. These include Janssen Pharmaceuticals, Astellas Pharma, and Bayer. Show Less Read more